Low Dose Naltrexone as it is known in the United States, or Lodonal as it is known internationally, has its origins in the FDA approved 50mg Naltrexone. Originally used to treat opiate dependences, the Immune Therapeutics patented treatments, which cover a wide range of indications (link to LDN patents), is currently used as an immune modulator.
OGF/MENK has been shown to halt the growth of the cells and is thought to allow immunological mechanisms (e.g. macrophages, natural killer cells) to accomplish the task of destroying the cancerous cells.
ORLANDO, FL AND DUBLIN, IRELAND / ACCESSWIRE / August 12, 2015 / Immune Therapeutics Inc., a U.S. public company (OTCQB: IMUN) in partnership with GB Pharma Holdings Inc and American Hospitals & Resort [AHAR], today announced that we received approvals from the Nigerian National Agency for Food and Drug Administration and Control [NAFDAC] for the importation of Lodonal(TM).
“We are pleased to receive the import license for Lodonal(TM) in Nigeria,” said Noreen Griffin Immune Therapeutics’ Chief Executive Officer. “This decision further enables the company to pursue Lodonal(TM) approvals in other emerging nations. It is almost impossible to express our thanks for the work of Dr Richards Afonja of AHAR and Dr. Gloria B. Herndon of GB Pharma. Without their continued support, the goal of bringing Lodonal(TM) to Nigeria would not have been possible. The import license is not the final step but an important next step in the process. Full authority to market Lodonal(TM) will be granted upon completion of the clinical trials. The Company hopes to be able to reach an agreement with FIDSON Healthcare Plc., in the coming weeks. We believe this distribution agreement will be key to optimizing the commercialization and launch of Lodonal(TM) making it available to benefit patients suffering from HIV and immune compromised diseases throughout Nigeria.”
Immune Therapeutics Inc., a U.S. public company [OTC:BB IMUN] in partnership with GB Pharma Holdings Inc and American Hospitals & Resort [AHAR], today announced that they have signed a Letter of Intent with Nigerian public company, Fidson Healthcare Plc [NSE:FIDSON.LG] one of Nigeria’s leading pharmaceutical companies
ORLANDO, Florida and Dublin, Aug. 3, 2015 (GLOBE NEWSWIRE) — via PRWEB – An agreement between Immune Therapeutics GB Pharma/AHAR with Fidson Healthcare will enable Fidson marketing, sales, customer support, and technical assistance organization to promote LodonalTM in Nigeria. This will elevate Immune Therapeutics and GB Pharma/AHAR distribution network to the next level. The distribution will become effective, upon completion of the ongoing NAFDAC approved 90-day Bridging trial evaluating the efficacy and safety of LodonalTM.
Tuesday May 5th Money Info Investment News Radio Show
Airs 10 AM to 11 AM EDT
The show is broadcast live on the internet and on the air from the studios of Radio Station WPSL AM 1590, Port St. Lucie, The Talk of the Treasure Coast
Mrs. Herndon will discuss her work with Immune Therapeutics to combat a variety of chronic, life-threatening diseases.
Immune Therapeutics is a specialty pharmaceutical company undergoing a wide range of FDA testing of therapeutic protocols preparatory to the manufacture, commercialization, marketing, and distribution of their patented therapies.
Their novel concepts entail enhancing and refining both the activation and modulation of the body’s natural immune system.